Literature DB >> 27064094

Identifying Gaps in Technology for Congenital Interventions: Analysis of a Needs Survey from Congenital Interventional Cardiologists.

Kamel Shibbani1, Damien Kenny2, Doff McElhinney3, Ziyad M Hijazi4, Tim Moran5.   

Abstract

We carried out a device-needs survey to evaluate the gaps in device and equipment availability for congenital interventional cardiologists. As the complexity and demand for more complete solutions to congenital heart lesions increase, there is a growing need for modification and development of devices and equipment to support this endeavor. The survey was sent out via e-mail to members of the Congenital Cardiovascular Interventional Study Consortium and the Society for Cardiac Angiography and Interventions with a reach of over 350 congenital interventionalists. Responses were received from 68 cardiologists in 8 countries. In terms of the most desired device, 41 % ranked bioresorbable stents as their first choice from a list of 12 possible devices. Similarly, 23 % ranked large covered stents as their first choice. Twenty-seven percent of participants believed bioresorbable stents would have the greatest potential to improve morbidity of their patients, with another 27 % reporting that covered stents would have the greatest impact. Fifty percent of participants reported that they would like to see large covered stents available in their country. These data point toward a perceived need for the development/approval of bioresorbable stents for the pediatric age group, as well as the need to approve the use of large covered stents in the pediatric age group in the USA.

Entities:  

Keywords:  Bioresorbable stent; Covered stent; Interventional cardiology; Survey

Mesh:

Year:  2016        PMID: 27064094     DOI: 10.1007/s00246-016-1372-0

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  10 in total

1.  Indications for cardiac catheterization and intervention in pediatric cardiac disease: a scientific statement from the American Heart Association.

Authors:  Timothy F Feltes; Emile Bacha; Robert H Beekman; John P Cheatham; Jeffrey A Feinstein; Antoinette S Gomes; Ziyad M Hijazi; Frank F Ing; Michael de Moor; W Robert Morrow; Charles E Mullins; Kathryn A Taubert; Evan M Zahn
Journal:  Circulation       Date:  2011-05-02       Impact factor: 29.690

2.  Covered stents for coarctation of the aorta: treating the interventionalist or the patient?

Authors:  Ziyad M Hijazi; Damien P Kenny
Journal:  JACC Cardiovasc Interv       Date:  2014-03-13       Impact factor: 11.195

3.  Transcatheter occlusion of the patent ductus arteriosus in infants: experimental testing of a new Amplatzer device.

Authors:  John L Bass; Neil Wilson
Journal:  Catheter Cardiovasc Interv       Date:  2013-10-23       Impact factor: 2.692

4.  A novel technique for transcatheter patent ductus arteriosus closure in extremely preterm infants using commercially available technology.

Authors:  Evan M Zahn; Phillip Nevin; Charles Simmons; Ruchira Garg
Journal:  Catheter Cardiovasc Interv       Date:  2014-05-20       Impact factor: 2.692

5.  Innovative resource utilization to fashion individualized covered stents in the setting of aortic coarctation.

Authors:  Damien Kenny; Qi-Ling Cao; Clifford Kavinsky; Ziyad M Hijazi
Journal:  Catheter Cardiovasc Interv       Date:  2011-09-01       Impact factor: 2.692

6.  Early restenosis following biodegradable stent implantation in an aortopulmonary collateral of a patient with pulmonary atresia and hypoplastic pulmonary arteries.

Authors:  Colin J McMahon; Paul Oslizlok; Kevin P Walsh
Journal:  Catheter Cardiovasc Interv       Date:  2007-04-01       Impact factor: 2.692

7.  First reported use of drug-eluting bioabsorbable vascular scaffold in congenital heart disease.

Authors:  B A McCrossan; C J McMahon; K P Walsh
Journal:  Catheter Cardiovasc Interv       Date:  2015-11-28       Impact factor: 2.692

8.  Morphologic characterization of the patent ductus arteriosus in the premature infant and the choice of transcatheter occlusion device.

Authors:  Ranjit Philip; B Rush Waller; Vijaykumar Agrawal; Dena Wright; Alejandro Arevalo; David Zurakowski; Shyam Sathanandam
Journal:  Catheter Cardiovasc Interv       Date:  2015-11-03       Impact factor: 2.692

9.  The off-versus on-label use of medical devices in interventional cardiovascular medicine?: Clarifying the ambiguity between regulatory labeling and clinical decision making, part III: structural heart disease interventions.

Authors:  Ralf Holzer; Ziyad Hijazi
Journal:  Catheter Cardiovasc Interv       Date:  2008-11-15       Impact factor: 2.692

Review 10.  Bioresorbable scaffolds for percutaneous coronary interventions.

Authors:  Bill D Gogas
Journal:  Glob Cardiol Sci Pract       Date:  2014-12-31
  10 in total
  4 in total

1.  Preclinical comparative assessment of a dedicated pediatric poly-L-lactic-acid-based bioresorbable scaffold with a low-profile bare metal stent.

Authors:  Kamel Shibbani; Luiza De Lima E Silva Bagno; Marie-France Poulin; Thomas Matella; Karim Diab; Clifford Kavinsky; Nagarajan Ramesh; Vinayak Bhat; Ziyad M Hijazi; Damien Kenny
Journal:  Catheter Cardiovasc Interv       Date:  2020-04-15       Impact factor: 2.692

2.  Bioresorbable Stent to Manage Congenital Heart Defects in Children.

Authors:  Jamie Wright; Annie Nguyen; Nandika D'Souza; Joseph M Forbess; Alan Nugent; Surendranath R Veeram Reddy; Robert Jaquiss; Tré Raymond Welch
Journal:  Materialia (Oxf)       Date:  2021-03-19

Review 3.  Interventional Cardiology for Congenital Heart Disease.

Authors:  Damien Kenny
Journal:  Korean Circ J       Date:  2018-03-29       Impact factor: 3.243

4.  Initial status and 3-month results relating to the use of biodegradable nitride iron stents in children and the evaluation of right ventricular function.

Authors:  Ling Sun; Jun-Jie Li; Yu-Kai Xu; Yu-Mei Xie; Shu-Shui Wang; Zhi-Wei Zhang
Journal:  Front Cardiovasc Med       Date:  2022-08-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.